Nucleai raises $33 million for spatial biology drug development platform

Israeli spatial biology startup Nucleai has raised $33 million in a Series B funding round led by Section 32 and Sanofi Ventures along with previous participating investors, such as top VC firm Grove Ventures. This funding brings the total investment in the company to $50 million. Nucleai, founded in 2018 by a team with experience in the Israeli military’s AI computer vision department, aims to improve cancer treatment by developing a platform that predicts patient response to oncological treatments. The technology allows for better prediction of treatment effectiveness, reduces the need for unnecessary testing, and enhances the development of new cancer drugs. Nucleai’s platform has gained rapid adoption by pharmaceutical companies worldwide.

>> Click here to read the full article originally published in CTech: https://www.calcalistech.com/ctechnews/article/rjiw007pg9